Novo Nordisk shares recover as FDA pledges to crack down on illegal weight-loss drug copies
Novo Nordisk shares rose on Friday after the FDA vowed to target illegal copycat drugs. This follows a sharp decline linked to cheaper weight-loss alternatives.
洞察:
The U.S. Food and Drug Administration has pledged to take swift action against companies mass-marketing unapproved copycat drugs, stating that it cannot verify the quality, safety, or effectiveness of these products. This announcement, made on February 6, 2026, follows the launch of a significantly cheaper compounded version of Wegovy by Hims & Hers Health, Inc. . The regulatory move has provided immediate support to Novo Nordisk A/S , the manufacturer of the FDA-approved weight-loss medicine, which has its headquarters in Denmark 
DK and operates extensively in the United States 
US.
DK and operates extensively in the United States US.
